Engene Therapeutics (ENGN) closed at $2.41 on November 13, 2026, up 5.7% from the previous close, on volume of 3,465,383 shares (30-day average 1,255,297).
Data as of November 13, 2026.
13-Nov-2026
enGene Holdings (ENGN) Receives a Hold from Guggenheim
TipRanks (Fri, 13-Nov 8:56 AM ET)
enGene rises after mid-stage trial data for bladder cancer therapy; Piper upgrades
Seeking Alpha News (Thu, 12-Nov 11:33 AM ET)
enGene Announces LEGEND Trial Results and FDA Alignment
TipRanks (Thu, 12-Nov 7:46 AM ET)
Analysts’ Top Healthcare Picks: enGene Holdings (ENGN), Janux Therapeutics Inc (JANX)
TipRanks (Thu, 12-Nov 7:30 AM ET)
enGene reports positive LEGEND trial data, plans detalimogene BLA submission
Seeking Alpha News (Thu, 12-Nov 1:39 AM ET)
Business Wire (Wed, 11-Nov 4:03 PM ET)
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
Business Wire (Wed, 11-Nov 4:01 PM ET)
enGene to Participate in Upcoming Investor Conferences
Business Wire (Fri, 6-Nov 8:00 AM ET)
enGene to Host KOL Webinar on October 15, 2026
Business Wire (Tue, 13-Oct 8:00 AM ET)
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire (Tue, 8-Sep 7:30 AM ET)
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Engene Therapeutics trades on the NASDAQ stock market under the symbol ENGN.
As of November 13, 2026, ENGN stock price climbed to $2.41 with 3,465,383 million shares trading.
ENGN has a beta of 0.00, meaning it tends to be less sensitive to market movements. ENGN has a correlation of 0.00 to the broad based SPY ETF.
ENGN has a market cap of $161.43 million. This is considered a Micro Cap stock.
In the last 3 years, ENGN traded as high as $18.40 and as low as $1.40.
ENGN has underperformed the market in the last year with a return of -71.4%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ENGN shares. However, ENGN has outperformed the market in the last 3 month and 2 week periods, returning +42.6% and +57.5%, while SPY returned -2.8% and -0.2%, respectively. This indicates ENGN has been having a stronger performance recently.
ENGN support price is $2.15 and resistance is $2.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENGN shares will trade within this expected range on the day.
